IFNA1 and hepatocellular carcinoma: Henceforth, there is a need to alternative antiviral therapy from the available armamentarium for CHC genotype 3 patients who are non-responders or relapsers to Peg-IFN and RBV therapy to stop viral replication and ultimate hepatic decompensation, and prevent HCC.